Quarterly ResultMay 7, 2026, 04:14 PM
Stoke Therapeutics Q1 Revenue Plunges to $6.23M; Net Loss $(50.0)M
AI Summary
Stoke Therapeutics reported a substantial decline in its first quarter 2026 financial performance, with revenue plummeting to $6.23 million from $158.57 million in the prior year's quarter. This led to a net loss of $(50.0) million, a significant reversal from the $112.88 million net income recorded in Q1 2025. Despite the financial downturn, the company increased its R&D and SG&A expenses and secured $80.7 million in net proceeds from a controlled equity offering, while also entering into a new long-term lease for expanded corporate headquarters and laboratory space.
Key Highlights
- Q1 2026 revenue decreased significantly to $6.23 million from $158.57 million in Q1 2025.
- The company reported a net loss of $(50.0) million for Q1 2026, compared to a net income of $112.88 million in Q1 2025.
- Basic and diluted net loss per share were $(0.79) for Q1 2026, down from basic EPS of $1.95 and diluted EPS of $1.90 in Q1 2025.
- Research and development expenses increased to $39.67 million in Q1 2026 from $32.68 million in Q1 2025.
- Sales, general and administrative expenses rose to $19.97 million in Q1 2026 from $14.65 million in Q1 2025.
- Net cash used in operating activities was $(60.58) million in Q1 2026, a shift from $131.83 million provided in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $343.55 million as of March 31, 2026.
- Issued approximately 2.6 million shares for net proceeds of $80.7 million under a controlled equity offering sales agreement.